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Abstract The LIM only protein Lmo2 plays an important role
in hematopoiesis and leukemogenesis. Lmo2 acts as a bridging
molecule between components of hematopoietic gene regulatory
protein complexes. We used the yeast two-hybrid system to
identify novel Lmo2 interacting proteins and found that the AF6
protein binds to Lmo2. AF6 is a recurrent fusion partner of
MLL, the human homolog of Drosophila trithorax chromatin
remodeling protein that is involved in childhood leukemia and
mixed lineage leukemia. Our data support the notion that
recurrent fusion partners of chimeric MLL proteins recruit
hematopoietic gene regulatory complexes. % 2002 Published
by Elsevier Science B.V. on behalf of the Federation of Euro-
pean Biochemical Societies.
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1. Introduction
Proteins with LIM domains play important roles in embryo
development and hematopoiesis [1^3]. The LIM signature rep-
resents protein interaction domains of approximately 50 ami-
no acids [2]. While many LIM proteins contain various addi-
tional domains such as homeodomains or kinase domains, a
subfamily that contains LIM domains only (Lmo) is thought
to mediate interaction between proteins [1,2].
Lmo2 (also called TTG2; RBTN2) is expressed in myeloid
and erythroid precursors of the hematopoietic system and its
expression decreases during di¡erentiation [4]. Chromosome
translocations a¡ecting both Lmo2 and the related Lmo1
genes were found in a subset of T cell acute lymphoblastic
leukemias, and ectopic expression of Lmo2 or Lmo1 induces
leukemia (see references in [3]). Disruption of the Lmo2 gene
has ¢rmly established its essential role in hematopoiesis [4,5].
Complexes containing Lmo2, GATA1, the helix-loop-helix
proteins Tal1/SCL, E47, Ldb1/NLI and the retinoblastoma-
binding protein 2 (RBP2) have been identi¢ed [6^9]. Accord-
ingly, it has been suggested that bridging between hemato-
poietic transcription factors is an important function of
Lmo2. We set out to identify novel Lmo2 interacting proteins.
Here we describe that Lmo2 interacts with the AF6 protein.
AF6 is a recurrent fusion partner of MLL, the human homo-
log of the Drosophila trithorax gene that is involved in epi-
genetic chromatin remodeling events and leukemogenesis
[10,11]. Our data raise the possibility that MLL^AF6 fusion
proteins interact with Lmo proteins through the AF6 moiety.
The results thus suggest a potential connection between hem-
atopoietic transcription factor complexes that play essential
roles in progenitor proliferation and di¡erentiation and be-
tween MLL^AF6 fusion proteins.
2. Materials and methods
2.1. Plasmid constructs and library screening
A PCR fragment encoding aa 27^158 of the human Lmo2 (vN-
Lmo2) was used in the yeast two-hybrid screens to screen a rat liver
library (Matchmaker, Clontech). Lmo2 mutant cDNAs were con-
structed by PCR and cloned into pGEX 4T1 (Pharmacia). Rat AF6
(rAF6) cDNA and mutants derived thereof were Flag-tagged and
cloned into pcDNA3 (InVitrogen). For the immunoprecipitation ex-
periments, full-length human Lmo2 was HA-tagged and cloned into
pcDNA1. rAF6 cDNA was cloned in frame with Gal4^DBD into
pcDNA3. Plasmid constructs were sequenced, and protein expression
was con¢rmed. GST pull-down assays were performed as described
elsewhere [25].
2.2. Transfection and co-immunoprecipitation experiment
QT6 quail ¢broblasts were transfected as previously described [25].
Whole cell lysates were prepared in RIPA bu¡er, supplemented with
protease inhibitors. Lysates (500 Wl) were incubated with 3 Wg of anti-
HA antibodies (Babco) or 5 Wg of anti-Gal4 antibodies overnight at
4‡C under gentle agitation. Protein G or protein A Sepharose (Phar-
macia) was added, incubated for 1 h, and washed extensively with
RIPA bu¡er. Immunoprecipitates were separated by SDS^PAGE,
blotted (Millipore) and co-precipitated proteins were revealed with
antisera directed against either HA, Gal4, or AF6 (Transduction Lab-
oratories). Immunoblots were developed with ECL (Amersham).
2.3. Reverse transcription-polymerase chain reaction
First strand cDNA was synthesized from total RNA using Super-
script1 II (Gibco). RT-PCR was performed with speci¢c primers for
MLL^AF6 (250 bp in ML-1 and 400 bp in CTS: forward GTCCA-
GAGCAGAGCAAACCAG and reverse CTGACATGCACTTCA-
TAGAGTG), Lmo2 (470 bp: forward ATGTCCTCGGCCATCGAA
and reverse ATCCCATTGATCTTAGTCCA), Ldb1/NLI (475 bp:
forward AGCTAAGAGGGCCCAGC and reverse CACACGGAGC-
CACTGTGCC), Tal1/SCL (481 bp: forward ACCACCAACAAT-
CGAGTGAAG and reverse GGATGGCAGGATGGAGGCT),
GATA2 (163 bp [26]), RBP2 (241 bp: forward TTCTGTGTTGAA-
CGGTTCTTGTCC and reverse CGATAAAGCTGAGCGGATC-
TGTGA). PCRs were performed by means of 35 cycles (25 cycles
for GAPDH) at an annealing temperature of 58‡C.
3. Results and discussion
A truncated form of human Lmo2 (aa 27^158; vN-Lmo2)
was fused to the Gal4 DNA binding domain and used as a
bait to identify Lmo2 interacting proteins by yeast two-hybrid
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Fig. 1. AF6 interacts with the LIM domains of Lmo2. A: Sche-
matic representation of human AF6 (hAF6) and the rAF6 isolate.
hAF6 contains two RAS-binding domains (RA), a U104 and DIL
domain as well as a PDZ domain and a proline-rich region (Pro)
[27,28]. The rAF6 retains 80 aa from the DIL domain, the PDZ do-
main (89% homology with hAF6 PDZ) and the Pro domain (83%
homology with hAF6 Pro). Alignments were done using the blast
search program; hAF6=NM005936.1. B: Schematic representation
of various deletion mutants of rAF6 fused to GST. After in vitro
translation and [35S]methionine labeling, rAF6 mutants (lane 1= in-
put 50%) were incubated with GST (lane 2) or GST^vN/vC-Lmo2
fusion protein (lane 3). Beads were extensively washed, bound pro-
teins were separated by SDS^PAGE and visualized by autoradiogra-
phy. C: Schematic representation of deletion mutants of Lmo2
fused to GST. LIM1, 2 (hatched and black box, respectively) repre-
sent the two LIM domains of Lmo2. Lmo2 mutants were tested for
their ability to bind to 35S-labeled in vitro translated rAF6.
Asterisks indicate point mutations introduced in the LIM domains.
Lane 1= input 65%; lane 2=GST; lane 3=GST^vN/vC-Lmo2;
lane 4=vLIM2; lane 5=vLIM2/C30S; lane 6=vLIM1; lane
7=vLIM1/D147A.
Fig. 2. Interaction of Lmo2 and rAF6 in vertebrate cells and co-ex-
pression of Lmo2 interacting proteins in MLL^AF6 leukemic cells.
A: QT6 ¢broblasts were transfected with HA-tagged Lmo2 (HA-
Lmo2) and Gal4 or Gal4^rAF6. Cells were harvested after 24 h and
subjected to immunoprecipitation using a HA-tag speci¢c antibody
(IP K-HA). Proteins were separated by SDS^PAGE, blotted and
probed with antibodies as indicated on the left. The panel on the
right shows expression controls of transfected constructs (Lysates).
B: QT6 were transfected as described in A. Protein extracts were
then subjected to immunoprecipitation using a Gal4-speci¢c anti-
body. Co-precipitated proteins (IP K-Gal4) were revealed by immu-
noblotting using antibodies indicated on the left. Expression con-
trols are shown on the right panel (Lysates). C: Co-expression of
Lmo2 and transcripts of interacting proteins in MLL^AF6 leukemia
cells. Total RNA was isolated from ML-1 (lane 1), CTS (lane 2),
HEL (lane 3), and Jurkat cells (lane 4); water control (lane 5). RT-
PCR was performed with speci¢c primers for MLL^AF6, Lmo2,
Tal1/SCL, GATA2, Ldb1/NLI, RBP2 and GAPDH, as indicated on
the left. Positive controls for Lmo2 and for GATA2, HEL cells; for
Tal1/SCL, Ldb1/NLI and RBP2, HEL and Jurkat cells. Note the
di¡erent size of the MLL^AF6 ampli¢ed fragments in the two pa-
tient cell lines, which is probably due to di¡erent breakpoints in the
translocations.
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screening of rat liver library. The N-terminal part of Lmo2
(aa 1^26) was omitted because it represents a transcriptional
activation domain [12,13]. From two million transformed
yeast clones, ¢ve clones were found to interact speci¢cally
with Lmo2. Sequence analysis revealed that a strongly inter-
acting prey construct encoded a C-terminal fragment of the
rAF6 protein, also called s-afadin [14,15], shown in Fig. 1A.
The Lmo2 interacting rAF6 clone retained the PDZ domain
and a proline-rich C-terminal domain (Fig. 1A). Both types of
domains have been previously shown by others to interact
with LIM domains [16,17]. Various rAF6 and Lmo2 mutants
were generated to con¢ne the interaction between rAF6 and
Lmo2. As shown in Fig. 1B, neither the PDZ domain nor the
proline-rich domain of rAF6 was required for Lmo2 binding.
However, a protein region between amino acid residues 1123
to 1373 of rAF6 was essential for Lmo2 binding. Data base
searches with this protein region did not reveal similarities
with other known proteins. Nevertheless, residues 1123 to
1373 are 92% identical to their human counterpart, suggesting
that the Lmo2 binding region is conserved in the hAF6. Next,
deletion mutants of Lmo2 were tested to determine which part
of Lmo2 binds to rAF6 (Fig. 1C). Constructs that contain
either both LIM domains or a single LIM domain still bound
to rAF6 (Fig. 1C, lanes 3, 4 and 6). However, point mutations
that disrupt the zinc-¢nger structure of LIM domains (D147A
in vLIM1 or C30S in vLIM2) entirely abrogated Lmo2^rAF6
interaction (Fig. 1C, lanes 5 and 7). These data indicate that
both LIM domains of Lmo2 can bind to rAF6 and that an
intact LIM domain structure is indispensable for interaction
with rAF6. Interestingly enough, we found that rAF6 also
binds to Lmo1 and to RIL in GST pull-down assays (data
not shown). Taken together, these results show that AF6 may
interact with various LIM proteins.
AF6 is normally expressed at the plasma membrane and
locates to the nucleus as an MLL^AF6 fusion protein [18].
An important question therefore was whether interaction be-
tween rAF6 and Lmo2 also occurs in the nucleus of vertebrate
cells. As we failed to express a full-length tagged version of
the MLL^AF6 fusion protein, we generated a Gal4^rAF6
expression construct that also localizes to the nucleus (con-
¢rmed by immunohistological staining, data not shown). Im-
munoprecipitation from transfected ¢broblasts revealed that
Gal4^rAF6, but not Gal4, co-precipitated along with HA-
tagged Lmo2 (Fig. 2A). Similarly, Lmo2 co-immunoprecipi-
tated together with Gal4^rAF6 but not with Gal4 when a
Gal4 speci¢c antiserum was used (Fig. 2B). These results
show that Lmo2 associates with a rAF6 fusion protein in
the nucleus.
Finally, we performed RT-PCR analysis to determine
whether Lmo2 interacting partner proteins (see Section 1)
are co-expressed with MLL^AF6 translocations. MLL^AF6
transcripts are expressed in the CTS and ML-1 cell lines that
were derived from patients with acute myeloid leukemia [18^
21]. As shown in Fig. 2C, Lmo2 is expressed in both CTS and
ML-1 cells along with GATA2, Ldb1/NLI and RBP2. More-
over, Tal1/SCL that has also been shown to interact with
Lmo2 [7,8] was expressed in CTS cells. These data show
that various Lmo2 partner proteins are co-expressed in cells
that carry the MLL^AF6 translocation. Further investigations
are required, however, to show unequivocally that hemato-
poietic gene regulatory complexes are recruited by MLL^
AF6 through Lmo2.
Taken together, our data show that Lmo2 binds to AF6, a
recurrent translocation partner of MLL. The MLL gene prod-
uct is implied in heritable changes in gene expression and has
been shown to be involved in more than 40 di¡erent recurrent
chromosome translocations. Although MLL leukemias are
potentially the result of dominant-negative functions of trun-
cated chimeric MLL proteins, a gain of function that deter-
mines phenotype and leukemogenic selection is also suggested
by the particular fusion partners [10,11]. It is therefore intri-
guing to see that other MLL-chimeras implicated in leukemo-
genesis have also been suggested to connect to the hemato-
poietic transcriptional apparatus [22^24]. The observation
that AF6 binds to Lmo2 represents a novel starting point to
examine how MLL fusion proteins reprogram hematopoiesis
and induce leukemia.
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